scholarly journals Glomerular filtration rate: new age- and gender- specific reference ranges and thresholds for living kidney donation

2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Anthony Fenton ◽  
Emma Montgomery ◽  
Peter Nightingale ◽  
A. Michael Peters ◽  
Neil Sheerin ◽  
...  
2021 ◽  
Vol 79 (1) ◽  
pp. 57-61
Author(s):  
Matthieu Gallet ◽  
Clément Drouet ◽  
Alina Berriolo-Riedinger ◽  
Alexandra Nicolas ◽  
Alexandre Cochet ◽  
...  

2021 ◽  
Vol 36 (Supplement_1) ◽  
Author(s):  
François Gaillard ◽  
Pierre Delanaye ◽  
Jessica Van Der Weijden ◽  
Geir Mjøen ◽  
Ingela Fehrman-Ekholm ◽  
...  

Abstract Background and Aims Studies of healthy individuals or candidates for living kidney donation, in various geographical areas and ethnic groups, describe a decline of glomerular filtration rate (GFR) with age. Most data on GFR are obtained from subjects in the general population or from candidates for kidney donation who are younger than 65 years. It is currently unknown whether the definition of normal GFR in subjects older than 65 years is similar to the definition in those younger than 65 years. Because the age of candidates for living kidney donation is increasing worldwide, lack of GFR references for older donors complicates the selection process. Moreover, older individuals are most likely to have a mildly decreased GFR that may be misinterpreted as chronic kidney disease. In this study, we calculated percentiles of measured GFR (mGFR) from a large cohort of effective kidney donors (EKD) younger than 65 years, and extrapolated them to subjects older than 65 years. Additionnaly, we collected mGFR data from different centers within Europe from EKD and/or healthy people (HP) from the general population older than 65 years. We tested if the distribution of mGFR of these older subjects fitted with the extrapolated percentiles. Method In this retrospective, observational, multi-center study, percentiles of mGFR in EKD were calculated from a development cohort of French and Belgian EKD younger than 65 years (n=1983). From the French kidney donor study, 147 EKD older than 65 years were considered as the internal validation cohort. In an external validation cohort, data on mGFR of subjects older than 65 years, either EKD or HP from the general population (from Germany, Sweden (2), Norway, Netherlands and France, n=2459) were included. Data were fully anonymized and this retrospective study was approved by the respective ethics committees. Percentiles were derived for the development database, using quantiles modeled as cubic splines with two linear parts joining at one age-knot of 40 years. The median quantile had a constant first part (slope of zero) and a second part with a negative slope of -0.88235 mL/min/1.73m² per year. To maintain consistency, all quantiles were adjusted to show the same shape as the medium quantile. Above 65 years, the percentile values were extrapolated using the same mathematical model. We then calculated the percentage of results from the internal and external validation cohorts that were within the 5th extrapolated percentile (P5) and 95th percentile (P95). A sensitivity analysis including the EKD only was performed. Results Individuals in the development cohort were younger than in the internal or external validation cohort (47.3±10.5 years vs. 68.8±2.9 years and 71.4±6.4 years; respectively, both p<0.001). Individuals in the development cohort had a higher mGFR than in the internal or external validation cohort (99.9±16.4 mL/min/1.73m2 vs. 86.4±14 mL/min/1.73m2 and 82.7±15.5 mL/min/1.73m2; respectively, both p < 0.001). Among the 147 EKD from the internal validation cohort, none (0%) had mGFR below the extrapolated P5 and12 (8.1%) had mGFR higher than the extrapolated P95. Consequently, 135/147 (91.2%) of subjects were between P5-P95. (Figure 1). Considering the whole external validation cohort (n=329), 5 subjects had mGFR lower than extrapolated P5 (1.5%), 25 were above P95, leaving 299 (90.9%) with mGFR between P5 and the extrapolated P95. Conclusion We demonstrate that extrapolated percentiles of mGFR (calculated in individuals younger than 65) fits well with the distribution of mGFR in individuals older than 65. Extrapolation of percentiles to individuals older than 65 is useful to define age-adapted GFR thresholds for older individuals.


2020 ◽  
Vol 9 (2) ◽  
pp. 338
Author(s):  
Julia Kerschbaum ◽  
Stefanie Bitter ◽  
Maria Weitlaner ◽  
Katrin Kienzl-Wagner ◽  
Hannes Neuwirt ◽  
...  

Living kidney donation represents the optimal renal replacement therapy, but recent data suggest an increased long-term renal risk for the donor. Here, we evaluated the risk for reduced estimated glomerular filtration rate (eGFR), death, and major cardiovascular events such as nonfatal myocardial infarction or cerebrovascular event including TIA (transient ischemic attack) and stroke in 225 donors, who underwent pre-donation examinations and live donor nephrectomy between 1985 and 2014 at our center. The median follow-up time was 8.7 years (1.0–29.1). In multivariate analysis, age and arterial hypertension at baseline were significantly associated with a higher risk of adverse renal outcomes, such as (1) eGFR <60 mL/min/1.73 m2 (age per year: HR (hazard ratio) 1.05, 95% confidence interval (CI) 1.03–1.08, hypertension: HR 2.25, 95% CI 1.22–3.98), (2) eGFR <60 mL/min/1.73 m2 and a decrease of ≥40% from baseline (age: HR 1.08, 95% CI 1.03–1.13, hypertension: HR 4.22, 95% CI 1.72–10.36), and (3) eGFR <45 mL/min/1.73 m2 (age: HR 1.12, 95% CI 1.05–1.20, hypertension: HR 5.06, 95% CI 1.49–17.22). In addition, eGFR at time of donation (per mL/min/1.73 m2) was associated with a lower risk of (1) eGFR <60 mL/min/1.73 m2 (HR 0.98, 95% CI 0.97–1.00) and (2) eGFR <45 mL/min/1.73 m2 (HR 0.95, 95% CI 0.90–1.00). Age was the only significant predictor for death or major cardiovascular event (HR 1.08, 95% CI 1.01–1.16). In conclusion, arterial hypertension, lower eGFR, and age at the time of donation are strong predictors for adverse renal outcomes in living kidney donors.


2009 ◽  
pp. 81-86
Author(s):  
Giuseppe Lippi ◽  
Nicola Tessitore ◽  
Martina Montagnana ◽  
Valeria Bedogna ◽  
Gian L. Salvagno ◽  
...  

1996 ◽  
Vol 100 (4) ◽  
pp. 1949-1967 ◽  
Author(s):  
Christopher H. Morrell ◽  
Sandra Gordon‐Salant ◽  
Jay D. Pearson ◽  
Larry J. Brant ◽  
James L. Fozard

Author(s):  
Nikolay V. Voskoboev ◽  
Timothy S. Larson ◽  
Andrew D. Rule ◽  
John C. Lieske

AbstractCystatin C is an alternative biomarker for assessing glomerular filtration rate (GFR), yet lack of standardization could hinder its widespread use. In this study we analytically and clinically validated a newer cystatin C particle-enhanced turbidimetric assay (PETIA) traceable to a certified reference material and compared it to the more commonly used particle-enhanced nephelometric assay (PENIA).Samples from four patient cohorts at the Mayo Clinic were studied: 1) clinical convenience samples (n=50); 2) samples from patients undergoing iothalamate urinary clearance testing for clinical indications (n=101); 3) volunteers without kidney disease (n=292); 4) samples from 1999–2000 with previous cystatin C measurements.The cystatin C PETIA was analytically robust between 0.15 mg/L and 8.36 mg/L. PETIA cystatin C values were 27.5% higher than PENIA results. Furthermore, PENIA results were 12.9% lower in 2010 than in 2000. PETIA cystatin C values and existing equations performed reasonably well to estimate GFR with an overall –7.4% bias for all patients analyzed. Age and gender specific reference intervals were established for the PETIA cystatin C.Cystatin C can be precisely measured by PETIA traceable to the international reference material, ERM-DA471/IFCC, using a routine chemistry autoanalyzer. There are important biases between this assay and the widely employed Siemens PENIA. This study highlights the importance of assay standardization if cystatin C is to be widely used to estimate GFR.


Sign in / Sign up

Export Citation Format

Share Document